Clinical Trials on Harmaiden alueiden lymfooma

Total 8563 results

Sequenom, Inc.

Completed

Determination of Performance Characteristics of the MassPLEX Factor II/V Leiden Test

Thrombosis | Factor V Leiden | Factor II

United States
National Taiwan University Hospital

Completed

Correlation of Genetic Polymorphism and Livedo Vasculitis

Livedo Vasculitis | Livedoid Vasculitis | Livedoid Vasculopathy | Genetic Pleomorphism | Leiden Mutation

Taiwan
University Hospital, Clermont-Ferrand
Diagnostica Stago

Recruiting

Evaluation of the Inter-center Variability of the Measurement of Thrombin Generation by the ST Genesia System (EVIGE)

Patients Without a Medical History of Thrombosis or Hemorrhage | Hemophilic Patient | Patient With FV Leiden Mutation | Patient With Cirrhosis | Patient on Anticoagulant

France
Centre Hospitalier Universitaire de Nīmes

Completed

Assessment of the Prevalence of Major Psychiatric Disorders in a Cohort of Women With Clinical Criteria Corresponding to Pure, Abortive-form, Obstetrical, Antiphospholipid Syndrome (NOHA-PSY)

Antiphospholipid Syndrome | Factor V Leiden Thrombophilia

France
Marcela V. Maus, M.D.,Ph.D.

Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Novartis Pharmaceuticals
Bristol-Myers Squibb

Recruiting

Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma

United States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
IGM Biosciences, Inc.
ADC Therapeutics S.A.

Active, not recruiting

A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCL

United States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
Zhejiang University
Shanghai First Song Therapeutics Co., Ltd

Not yet recruiting

An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory Lymphoma

Hodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell Lymphoma

China
SymBio Pharmaceuticals

Completed

Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Follicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, Diffuse

Japan, Korea, Republic of
Massachusetts General Hospital
TG Therapeutics

Active, not recruiting

Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma

Lymphoma | Follicular Lymphoma | Marginal Zone Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma Grade IIIa | Marginal Zone B Cell Lymphoma | Follicular Lymphoma Grade 2

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | B-Cell Non-Hodgkin Lymphoma | Adult Diffuse Large B-Cell Lymphoma | T-Cell Non-Hodgkin Lymphoma

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | Small Lymphocytic Lymphoma | Lymphoproliferative Disorder | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Grade 3 Follicular... and other conditions

United States, Canada, Australia, Puerto Rico
Massachusetts General Hospital
National Comprehensive Cancer Network

Completed

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Follicular Lymphoma | Mantle Cell Lymphoma | Non-Hodgkin Lymphoma | Peripheral T-cell Lymphoma | Diffuse Large B-cell Lymphoma

United States
Novartis Pharmaceuticals

Completed

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL

Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma

United States, Belgium, Germany, France, Italy, Korea, Republic of, Spain, Turkey
Ruijin Hospital
The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaborators

Not yet recruiting

A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological Types

Lymphoma | Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Mucosa-Associated Lymphoid Tissue Lymphoma | Intravascular Large B-Cell Lymphoma | Extranodal Lymphoma | NK/T-Cell Lymphoma, Nasal and Nasal-Type

China
University of Washington
AstraZeneca

Recruiting

Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma

B-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...

United States
Iksuda Therapeutics Ltd.

Recruiting

IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin Lymphoma

Australia, Canada, United States
Epizyme, Inc.

Completed

Open-Label, Multi-Center, Two-Part, Ph1 Study to Characterize the PKs of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the ADME of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Adv Solid Tumors

Follicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal Lymphoma

United Kingdom
Robert Lowsky
National Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide Foundation

Completed

TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
H. Lee Moffitt Cancer Center and Research Institute
BeiGene, Ltd.

Recruiting

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

Follicular Lymphoma | Marginal Zone Lymphoma | B-Cell Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Janssen Scientific Affairs, LLC; Novartis Pharmaceuticals

Completed

A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma

Lymphoma | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma

United States
BeiGene

Completed

BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Marginal Zone Lymphoma

China
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell... and other conditions

United States
Massachusetts General Hospital
Varian Medical Systems

Recruiting

Adaptive Bridging RT in R/R B-cell Lymphoma (Pre-CAR T)

Lymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell Lymphoma

United States
Juno Therapeutics, a Subsidiary of Celgene

Active, not recruiting

Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)

Follicular Lymphoma | Non-Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma | Mantle-cell Lymphoma

United States
Fate Therapeutics

Withdrawn

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Transformed Indolent Non-Hodgkin's Lymphoma
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Lymphoma Study Association

Completed

Lenalidomide and R-CHOP in B-cell Lymphoma (R2CHOP-1)

Lymphoma, Large B-Cell, Diffuse | Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

France
BioNova Pharmaceuticals (Shanghai) LTD.

Terminated

Study of BN301, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Follicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Non Hodgkin Lymphoma | Diffuse Large B Cell Lymphoma

China
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Amgen

Terminated

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Diffuse Large B-cell Lymphoma(DLBCL)

United States, Canada, Germany, Belgium
Tessa Therapeutics

Active, not recruiting

Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma (CERTAIN)

Anaplastic Large Cell Lymphoma | Diffuse Large B Cell Lymphoma | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

United States
Kami Maddocks
National Cancer Institute (NCI)

Completed

Pembrolizumab and Ibrutinib in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Mantle Cell Lymphoma | Recurrent Burkitt Lymphoma | Recurrent... and other conditions

United States
Royal Marsden NHS Foundation Trust

Unknown

Blood Immunophenotyping in Staging of Indolent B-cell Lymphomas V1.0 (BMPB)

Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Marginal Zone Lymphoma (MZL)

United Kingdom
Amgen

Completed

Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

Lymphoma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma | Diffuse Large Cell Lymphoma | Low Grade Lymphoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma

Mantle Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Refractory Indolent Adult Non-Hodgkin Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Recurrent Indolent Adult Non-Hodgkin Lymphoma

United States
Eden BioCell Ltd.
National Taiwan University Hospital

Terminated

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Acute Lymphoblastic Leukemia | High-grade B-cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

Taiwan
Enterome

Recruiting

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma (SIDNEY)

Follicular Lymphoma | Marginal Zone Lymphoma

United States, Italy, Spain
Centre Hospitalier Universitaire Dijon

Not yet recruiting

Living Conditions of Patients With Diffuse Large B-Cell Lymphoma or Follicular Lymphoma in the Côte d'Or Region (LymphoVi)

Follicular Lymphoma | Diffuse Large Cell Diffuse Lymphoma

France
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
Fondazione Italiana Linfomi ONLUS
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Unknown

Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (REAL07)

Follicular Lymphoma | Non Hodgkin Lymphoma

Italy
SymBio Pharmaceuticals

Completed

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Japan
BeiGene

Completed

Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Cutaneous T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Anaplastic Large Cell Lymphoma, ALK-Positive | Extranodal NK/T-cell Lymphoma, Nasal Type | Peripheral T Cell Lymphoma | Extranodal NK/T-cell Lymphoma | Peripheral... and other conditions

China, Taiwan, Germany, France, Canada, Italy
He Huang

Recruiting

A Study of RD14-01 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma

China
Washington University School of Medicine
Genentech, Inc.

Recruiting

Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma

B Cell Lymphoma | Diffuse Large B Cell Lymphoma | High-grade B-cell Lymphoma | Transformed Lymphoma | Aggressive Lymphoma | Follicular Lymphoma Grade 3

United States
Pell Bio-Med Technology Co., Ltd.

Recruiting

Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy

Diffuse Large B Cell Lymphoma | Primary Mediastinal Large B Cell Lymphoma | Large B-cell Lymphoma | Follicular Lymphoma Grade 3B | Follicular Lymphoma Grade 3A

Taiwan
Reid Merryman, MD
Genentech, Inc.

Recruiting

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

Follicular Lymphoma | Marginal Zone Lymphoma | Indolent Non-hodgkin Lymphoma

United States
Peter MacCallum Cancer Centre, Australia
GlaxoSmithKline; Merck Sharp & Dohme LLC

Terminated

A Pilot Study of Oral Vorinostat Plus Oral Eltrombopag Support in Patients With Lymphoma (VEIL) (VEIL)

Follicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma

Australia
University of Nebraska
Bristol-Myers Squibb

Recruiting

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

Follicular Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | Relapsed Non-Hodgkin Lymphoma | Mediastinal Large B-cell Lymphoma | Indolent B-Cell Non-Hodgkin Lymphoma

United States
Narendranath Epperla

Withdrawn

Acalabrutinib and Duvelisib for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

Recurrent Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Refractory Marginal Zone Lymphoma | Refractory Nodal Marginal Zone Lymphoma | Recurrent Nodal Marginal Zone Lymphoma | Recurrent Splenic Marginal Zone Lymphoma | Refractory Splenic Marginal Zone Lymphoma and other conditions

Clinical Trials on Harmaiden alueiden lymfooma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Italy

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations